Friday, May 28, 2010

The Department of Veterans Affairs CIO Says no to Breast Cancer Genomics



The Department of Veterans Affairs CIO Says no to Breast Cancer Genomics




The Department of Veterans Affairs CIO Says no to Breast Cancer Genomics being added to The Veterans Affairs New VISTA S.O.A stratergy.

Scott Cragg, Special Assistant to the CIO, U.S. Department of Veterans Affairs and his Team.
John Teeter, Deputy Chief Information Officer, Department of Health and Human Services. CAPT Michael Weiner, Chief Medical Officer for the Defense Health Information Management System (DHIMS) Ed Meagher, Director, Strategic Healthcare Initiatives, SRA International; former Deputy Chief Information Officer, Dept. of Veterans Affairs (moderator) made their comments at the
AFFIRM The Association for Federal Information Resources Management ( http://affirm.org/ )May Monthly Luncheon on Health IT

The Department of Veterans affirs has a new System Called Veterans Health Information Systems and Technology Architecture (VISTA) said that they are not Including Genomics as a part of their VISTA system.

Genomics is the study of complex sets of genes, how they are expressed in cells (what their level of activity is), and the role they play in biology. Another way to think about it is as a small network of genes and how they work together to influence the a Veterans Breast CancerTumor's biology and behavior.

VISTA is built on a client-server architecture, which ties together workstations and personal computers with graphical user interfaces at Veterans Health Administration (VHA) facilities, as well as software developed by local medical facility staff. VISTA also includes the links that allow commercial off-the-shelf software and products to be used with existing and future
technologies. The Decision Support System (DSS) and other national databases that might be derived from locally generated data lie outside the scope of VISTA.

Hybrid Medical Analytics Our focus is on Genomic Trials. Genomics Science looks at groups of genes and how active they are. This activity can influence how a cancer is likely to grow and respond to treatment. Unlike a genetic test, that provide information about a person's inherited genetic make-up. Instead,

Hybrid Medical Analytics
looks at 21 genes in a patient's breast tumor trials to understand how these genes interact and influence the tumor's behavior.


Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems


Hybrid Medical Electronic e-Clinicals and early stage trials that allows
us unique insight into the most prevalent challenges at this phase of
testing. We have strategically built an infrastructure, methodology
and facility that meet those needs.

Saturday, May 22, 2010

82% Increase in Transgenic R&D for Breast Cancer that is Carcinogenesis caused by Li-Fraumeni Syndrome


82% Increase in Transgenic R&D for Breast Cancer that is carcinogenesis caused by Li-Fraumeni syndrome. Hybrid Medical focused on:

Family history and other risk factors for breast Cancer.
Models for predicting breast cancer risk.
Major genes associated with breast cancer
Screening and risk modification for hereditary breast cancer
Psychosocial issues associated with hereditary breast cancer

Among women, breast cancer is the most commonly diagnosed cancer after nonmelanoma skin cancer.

The syndromes most strongly associated with Breast cancers are BRCA1 or BRCA2 mutation syndromes. Breast cancer is also a common feature of Li-Fraumeni syndrome due to P53 mutations.

Breast Cancer research for a cure has a new friend. P53 or mP53. Mutant in transgenic mice has shown promise in the cure for Breast Cancer. Hybrid Medical e-Clinical generated transgenic
mice carrying mutant p53. We cloned the m53 cDNA from a radiation-induced mouse tumor.

The tumors was treated via a potent atelocollagen suppression of the tumors growth. The Result that mp53 activity caused tumors that can be suppressed by subsequent silencing of the mp53.

This is great news because if you get a Genomics Test and discover that you have Brac1 or Brac2one of the major causes of Breast Cancer, the mP53 Mutant can be suppressed and extend Life

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems